Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

iSpecimen Inc. (ISPC) vs ProPhase Labs, Inc. (PRPH)

iSpecimen Inc. and ProPhase Labs, Inc. are both Diagnostics & Research companies. iSpecimen Inc. is the larger, with a market value of $3.1M against $1.2M — 2.7× the size. ProPhase Labs, Inc. grew revenue faster over the last twelve months: −43.5% against −92.1%. ProPhase Labs, Inc. has the higher net margin (−717.4% vs −2,449.0%) and the lower return on invested capital (−387.3% vs 0.00%). Across the 17 metrics below, ProPhase Labs, Inc. leads on 12 and iSpecimen Inc. on 5.

Valuation

Metric ISPC PRPH Diagnostics & Research median
P/E n/m n/m 33.95
P/S 3.77 0.04 4.87
P/B 1.01 n/m 3.12
Price to free cash flow n/m n/m 34.02
EV/EBITDA 0.31 n/m 25.20
EV/Sales (5.55) 1.84 5.66
Earnings yield (4,479.37%) (23,896.00%) (1.75%)
Free cash flow yield (617.94%) (3,945.49%) (0.13%)

Profitability

Metric ISPC PRPH Diagnostics & Research median
Gross margin (108.26%) 16.38% 50.89%
Operating margin (2,020.05%) (498.73%) (8.57%)
Net margin (2,449.02%) (717.43%) (6.37%)
Free cash flow margin (1,866.61%) (175.22%) 0.00%
Return on equity (968.44%) (543.95%) (2.92%)
Return on assets (170.09%) (45.53%) (6.71%)
Return on invested capital 0.00% (387.30%) 0.00%

Growth

Metric ISPC PRPH Diagnostics & Research median
Revenue growth (TTM) (92.11%) (43.52%) 7.69%
EPS growth (last fiscal year) 87.03% 93.33% —
Revenue growth, 5-year CAGR (25.10%) (21.43%) 7.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ISPC PRPH Diagnostics & Research median
Debt to equity 0.00 (1.82) 0.11
Current ratio 0.82 0.05 2.02
Net debt to EBITDA 0.95 (0.74) 0.78

Dividend

Metric ISPC PRPH Diagnostics & Research median
Dividend yield — — 0.70%
Payout ratio 0.00 0.00 0.00

Size

Metric ISPC PRPH Diagnostics & Research median
Market cap 3.12m 1.17m 2.56b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack